04/01/2021

Dear Research Participant (or name):

You are currently participating in the research study EA2142: Randomized Phase II Study of Platinum and Etoposide versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-Small Cell Gastroenteropancreatic Neuroendocrine Tumors including Poorly Differentiated Neuroendocrine Carcinomas and Well-Differentiated Neuroendocrine Neoplasms.

We are writing to you because we have new information about this research study. As you are a participant in this research study, it is very important that you read this letter.

**WHAT HAS HAPPENED?**

We now have enough information to reach a conclusion that may be important to you as a participant.

From the information we now have, we know that:

* Participants who were treated with capecitabine and temozolomide are not likely to have their cancer’s growth controlled for as long a time as those participants who were treated with etoposide combined with either cisplatin or carboplatin.

Based on these results, no new participants will be enrolled in the study.

**ASK YOUR DOCTOR**

It is important that you discuss these findings with your doctor and how they apply to you:

* Study participants taking capecitabine and temozolomide may continue to take those drugs, or change treatment to etoposide combined with either cisplatin or carboplatin. That decision will be left to the participant and his or her treating physician.
* Study participants being treated with etoposide combined with either cisplatin or carboplatin should continue on the same treatment.
* Those participants who have already completed their treatment will continue to be followed as described in the study’s informed consent form.

Your continued participation in this research is important to us. Even if you change treatment to etoposide combined with either cisplatin or carboplatin, we still wish to follow you and learn as much as we can about the treatment of neuroendocrine cancers.

Please use the form on the next page to indicate if you agree to continue your participation in EA2142.

**THANK YOU**

You have been a very important part of this study, and we thank you for your participation.

The results from this study are very important and will help future individuals who are diagnosed with neuroendocrine tumors.

Questions regarding this notice should be directed to Bruce Giantonio, ECOG-ACRIN Executive Officer, at bgiantonio@ecog-acrin.org.

EA2142 Informed Consent Form – Addendum

Please indicate your choice by checking the appropriate box:

\_\_\_\_ I have reviewed this information with my doctor and I agree to continue my participation the EA2142 research study

\_\_\_\_ I have reviewed this information with my doctor and I do not want to continue my participation in the EA2142 research study.

Patient Signature:

Print Name:

Date: